RxDoctor Payments DataLook up a doctor →

Theodore Kelbel, MD

Allergy & Immunology · Grand Rapids, MINPI 1326333444

Payments from drug & device makers

$695,339in general payments, 2019–2025

Across 1,172 payments — averaging $593.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$159K
  • GSK$94K
  • Takeda Pharmaceuticals U.S.A., Inc.$85K
  • Sanofi$65K
  • Genentech USA, Inc.$64K
  • Regeneron Healthcare Solutions, Inc.$50K
  • plus $179K from 34 others

What the payments were for

  • Consulting fees$81,30312%
  • Speaking & faculty fees$552,21879%
  • Travel & lodging$39,6926%
  • Food & beverage$21,9333%
  • Education$1920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$695,339 in reported general payments places this provider in the 90th percentile of 119 allergy & immunology providers in Michigan.

See all allergy & immunology providers in Michigan

Medicare billing

Part B allowed, 2024
$3,075
Medicare patients
24
Services billed
98

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo38$1,676,034
IcatibantIcatibant Acetate14$268,525
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$14,194
Spiriva RespimatTiotropium Bromide18$9,251
Ipratropium Bromide57$1,957
Azelastine Hcl25$719
Albuterol Sulfate HfaAlbuterol Sulfate17$637
Montelukast Sodium56$635
Famotidine28$408
Fluticasone Propionate14$244
Hydroxyzine Hcl11$176
Prednisone11$19

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$84,740$1,676,03438 claims
GSKTrelegy Ellipta$93,955$14,19423 claims
Boehringer IngelheimSpiriva Respimat$17,159$9,25118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 119 allergy & immunology providers in Michigan.

Other allergy & immunology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →